Enjoy complimentary customisation on priority with our Enterprise License!
Below are some of the key findings from the hemophilia A therapeutics market analysis:
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The increased demand for prophylactic treatment for hemophilia A is one of the critical reasons that will drive the hemophilia A therapeutics market’s growth. This treatment minimizes the risk of developing inhibitors and prevents bleeding episodes. Prophylactic clotting factor regimen not only prevents hemarthrosis that is associated with hemophilia A but also avoids chronic microhemorrhage into joints. Many patients are using long-acting recombinant factor VIII therapies as prophylactic treatments.
The emergence of novel convenient approaches is gaining prominence in the market as they offer long-lasting therapeutic benefits from bleeding episodes. This will drive the hemophilia A therapeutics market to grow at a CAGR of almost 7% during the forecast period. AFSTYLA is one of the best examples of long-lasting therapy that is used to reduce the frequency of bleeding episodes in patients with hemophilia A.
The hemophilia A therapeutics market is fairly fragmented. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this hemophilia A therapeutics industry analysis report will allow the clients to identify new growth opportunities and design innovative strategies to improve their share in the market.
The report offers a complete analysis of various companies including:
The Americas will contribute the highest market share throughout the forecast period. The new drug approvals of long-acting and curative therapies for hemophilia A is one of the primary reasons for the high growth of the hemophilia A therapeutics market in this region.
The recombinant therapies segment will account for the highest market share in the hemophilia A therapeutics market as recombinant therapies that treat hemophilia A are safer than plasma-derived products.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
PART 10: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
PART 15: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.